AbCellera Biologics ABCL
NASDAQ ABCL
$11.70 -0.23 (-1.93%)
As of: Oct 20, 2026 · 3:59 PM EDT

AbCellera Biologics (ABCL) Current Debt (2020)

Updated

AbCellera Biologics (ABCL) reported Current Debt of -$387,000 for FY2020, compared with $387,000 in FY2019.

Analysis

AbCellera Biologics (ABCL) Current Debt (2020) Analysis & Trends

  • According to Business Quant data, Current Debt came in at $387,000 in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Debt (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn 3.51 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn -5.75 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn -
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn -
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn 208.00 Mn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn -
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn -
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn -
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn 64.00 Mn
10 AbCellera Biologics 3.58 Bn 3.04 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2020 -387,000.00
API Access

AbCellera Biologics Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-debt&ticker=ABCL&period=max&api_key=YOUR_API_KEY